Covid-19 roundup: Oxford investigator says vaccine rollout possible by end of this year; Fosun drops BioNTech vaccine to pursue Pfizer-partnered candidate instead
U.S. FDA warns about false positive results from Covid-19 antigen tests
Regeneron’s COVID-19 antibody cocktail therapy hits safety problem
Regeneron, Lilly Setbacks Raise Questions on the Effectiveness of Antibodies in Severe COVID-19
BDX Inks Deal With Dutch Gov. For 9M Covid-19 Antigen Tests
All Eyes on Moderna's COVID-19 Vaccine Ahead of Data Readout
Regeneron Halts Covid-19 Trial For High-Flow Oxygen Patients; Shares Fall
COVID Vaccine Fallout: General Air Cargo, Wait Your Turn
Regeneron to stop enrolling very sick Covid-19 patients in antibody trials
Eli Lilly Nabs $312.5M US Army Contract For Covid-19 Treatment
Regeneron posts second look on Covid-19 antibody cocktail, boosting its case for EUA — but what about symptom alleviation?
Healthcare And Biotech Outlook –Final Quarter of 2020
Moderna on track to report late-stage Covid-19 vaccine data
Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3%
Remdesivir for COVID-19: FDA approved but still unproven
Eli Lilly Strikes $375M Covid-19 Antibody Supply Deal With US Government
Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 trial; Novavax delays PhIII trial in US, with PhII data coming Friday
Pfizer or Merck: Which Pharma Stock Has More Upside Potential?
Regeneron’s Covid-19 antibody treatment cut medical visits in trial
Gilead cuts 2020 sales outlook as Covid-19 drug remdesivir falls short
These 3 Penny Stocks Could Rack up Triple-Digit Gains, Says Leerink
Most people mount a strong antibody response to SARS-CoV-2 that does not decline rapidly
U.S. strikes deal with Lilly for potential Covid-19 antibody drug
Pfizer Enters Final Stretch of Late-Stage Covid-19 Vaccine Trial
Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 trial; Novavax delays PhIII trial in US, with PhII data coming Friday;
Covid-19 roundup: Novavax delays PhIII trial in US, with PhII data coming Friday; CBER director promises 'safe and effective' vaccine in op-ed
US Hospitalizations Soar Almost 40% In One Week; Wisconsin Sees New COVID-19 Record: Live Updates
Eli Lilly Ends Covid-19 Trial In Hospitalized Patients On Disappointing Data
Good Entry Point for Gilead Sciences (GILD)? Not Just Yet, Says Analyst
South Korea pharma Celltrion’s Covid test gets U.S. emergency use authorization